In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...
Read MoreEvaluating isatuximab for patients with recurrent or non-responding multiple myeloma
